Prime Minister Opens e-Therapeutics’ Drug Discovery Centre near Oxford
News Feb 27, 2012
e-Therapeutics has announced that the UK’s Prime Minister, the Right Honourable David Cameron, MP, has opened the Company’s new drug discovery centre at Long Hanborough near Oxford.
The centre, which is located in the Prime Minister’s parliamentary constituency, will spearhead e-Therapeutics’ pioneering work in network pharmacology, a distinctive approach to the discovery of medicines with potential to produce new and improved treatments for complex diseases such as cancer.
The Prime Minister said: “e-Therapeutics is a fascinating and innovative business in my constituency. Their use of pioneering science has the potential to deliver great results and I very much hope that their treatments are successful.”
Professor Malcolm Young, founder and CEO of e-Therapeutics, said: “We are delighted to have the Prime Minister open our new drug discovery centre near Oxford, which is a world centre of excellence in the science that underpins our business.”
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Bacteria Produce More Substances Than Genetics PredictedNews
Tandem mass spectrometry has revealed that Streptomyces chartreusis, an antibiotic-producing bacterium, releases more metabolites into the surrounding medium than scientists assumed based on the analysis of the genome. They might include molecules that are of interest as potential pharmaceutical agents.READ MORE